What do the next 100 years hold for pneumococcal vaccination?

References

• Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine16, 1396–1400 (1998).
   PubMed Web of Science ®Google Scholar
• Wright AE, Parry Morgan W, Colebrook L, Dodgson RW. Observations on prophylactic inoculation against pneumococcus infections, and on the results which have been achieved with it. Lancet1, 1–10 (1914).
   Google Scholar
• Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J. Clin. Microbiol.10, 2759–2762 (1995).
   Google Scholar
• Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical and serological characterization. Microbiology156, 555–560 (2010).
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, Paton JC et al. Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis.188, 339–348 (2003).
   PubMed Web of Science ®Google Scholar
• Briles DE, Hollingshead SK, King J et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis.182, 1694–1701 (2000).
   PubMed Web of Science ®Google Scholar
• Ogunniyi AD, LeMessurier KS, Graham RM et al. Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect. Immun.75, 1843–1851 (2007).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R. Planning for a second (23 valent) generation pneumococcal vaccine. With special reference to new developments in our understanding of the structure and biology of polysaccharides. Bull. Eur. Physiopathol. Respir.19, 215–226 (1983).
   PubMedGoogle Scholar
• Dixon JM, Lipinski AE. Pneumococcal serotypes causing bacteremia and meningitis: relevance to composition of pneumococcal vaccine. Can. Med. Assoc. J.25, 263–267 (1981).
   Google Scholar
• Cornu C, Yzèbe D, Léophonte P et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine19, 4780–4790 (2001).
   PubMed Web of Science ®Google Scholar
• Robbins FC, Robbins JB. Current status and prospects for some improved and new bacterial vaccines. Ann. Rev. Public Health7, 105–125 (1986).
   PubMedGoogle Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA et al. EPIVAC Study Group. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect. Dis.10, 73 (2010).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Pneumococcal vaccination in the United States and 20 other developed countries, 1981–1996. Clin. Infect. Dis.26, 1117–1123 (1998).
   PubMed Web of Science ®Google Scholar
• Griffioen AW, Franklin SW, Zegers BJ, Rijkers GT. Expression and functional characteristics of the complement receptor type 2 on adult and neonatal B lymphocytes. Clin. Immunol. Immunopathol.69, 1–8 (1993).
   PubMedGoogle Scholar
• Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJ. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect. Immun.59, 1839–1845 (1991).
   PubMed Web of Science ®Google Scholar
• Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev.176, 154–170 (2000).
   PubMed Web of Science ®Google Scholar
• Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins: V. The immunological specificity of an antigen prepared by combining the capsular polysaccharide of type III pneumococcus with foreign protein. J. Exp. Med.54, 437–447 (1931).
   PubMedGoogle Scholar
• Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect. Dis.8, 435–443 (2008).
   PubMed Web of Science ®Google Scholar
• Ojo LR, O’Loughlin RE, Cohen AL et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine8(7), 435–443 (2010).
   Google Scholar
• Rennels MB, Edwards KM, Keyserling HL et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics101, 604–611 (1998).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J.19, 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Active bacterial core surveillance of the emerging infections program network. decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N. Engl. J. Med.348, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Fenner F, Henderson DA, Arita L, Jezek Z, Ladnyi ID. Smallpox and its Eradication. WHO, Geneva, Switzerland (1988).
   Google Scholar
• Beall B, McEllistrem MC, Gertz RE Jr et al.; Active Bacterial Core Surveillance Team. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J. Clin. Microbiol.44, 999–1017 (2006).
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297, 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med.360, 244–256 (2009).
   PubMed Web of Science ®Google Scholar
• Reinert RR, Paradiso P, Fritzell B. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe. Expert Rev. Vaccines9, 229–236 (2010).
   PubMed Web of Science ®Google Scholar
• Reinert R, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine28, 4249–4259 (2010).
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine27, 7257–7269 (2009).
   PubMed Web of Science ®Google Scholar
• van Effelterre T, Moore MR, Fierens F et al. A dynamic model of pneumococcal infection in the United States: implications for prevention through vaccination. Vaccine28, 3650–3560 (2010).
   PubMed Web of Science ®Google Scholar
• Antao VC, Hausdorff WP. Global epidemiology of pneumococcal disease – new prospects for vaccine control. Adv. Exp. Med. Biol.634, 19–29 (2009).
   PubMedGoogle Scholar
• De Wals P, Black S, Borrow R, Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin. Ther.31, 2152–2169 (2009).
   PubMed Web of Science ®Google Scholar
• Meerveld-Eggink A, de Weerdt O, Rijkers GT, van Velzen-Blad H, Biesma DH. Vaccination coverage and awareness of infectious risks in patients with an absent or dysfunctional spleen in The Netherlands. Vaccine26, 6975–6979 (2008).
   PubMedGoogle Scholar
• Leemans R, Harms G, Rijkers GT, Timens W. Spleen autotransplantation provides restoration of functional splenic lymphoid compartments and improves the humoral immune response to pneumococcal polysaccharide vaccine. Clin. Exp. Immunol.117, 596–604 (1999).
   PubMed Web of Science ®Google Scholar
• Langley JM, Dodds L, Fell D, Langley GR. Pneumococcal and influenza immunization in asplenic persons: a retrospective population-based cohort study 1990–2002. BMC Infect. Dis.10, 219 (2010).
   PubMed Web of Science ®Google Scholar
• Hartkamp A, Mulder AH, Rijkers GT, van Velzen-Blad H, Biesma DH. Antibody responses to pneumococcal and Haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine19, 1671–1677 (2001).
   PubMed Web of Science ®Google Scholar
• Segal BH, Freifeld AG, Baden LR et al. Prevention and treatment of cancer-related infections. J. Natl Comp. Cancer Netw.6, 122–174 (2008).
   PubMedGoogle Scholar
• van der Velden AM, Claessen AM, van Velzen-Blad H et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine25, 8512–8517 (2007).
   PubMed Web of Science ®Google Scholar
• Rijkers GT, Sanders LA, Zegers BJ. Anti-capsular polysaccharide antibody deficiency states. Immunodeficiency5, 1–21 (1993).
   PubMedGoogle Scholar
• Hak E, Grobbee DE, Sanders EA et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth. J. Med.66, 378–383 (2008).
   PubMed Web of Science ®Google Scholar
• Sanders LA, Feldman RG, Voorhorst-Ogink MM et al. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils. Infect. Immun.63, 73–81 (1995).
   PubMed Web of Science ®Google Scholar
• Wiertsema SP, Baynam G, Khoo SK et al. Impact of genetic variants in IL-4, IL-4 RA and IL-13 on the anti-pneumococcal antibody response. Vaccine25, 306–313 (2007).
   PubMed Web of Science ®Google Scholar
• Wiertsema SP, Veenhoven RH, Walraven V et al. Pneumococcal vaccine efficacy for mucosal pneumococcal infections depends on Fcγ receptor IIa polymorphism. Vaccine24, 792–797 (2006).
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin. Biol. Ther.8, 1659–1667 (2008).
   PubMed Web of Science ®Google Scholar
• Reif DM, Motsinger-Reif AA, McKinney BA, Rock MT, Crowe JE Jr, Moore JH. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination. Genes Immun.10, 112–119 (2009).
   PubMed Web of Science ®Google Scholar
• Brooks WA. A four-stage strategy to reduce childhood pneumonia-related mortality by 2015 and beyond. Vaccine27, 619–623 (2009).
   PubMedGoogle Scholar